Table 3.
Characterization of selected six neutralization mAbs (purified mAbs).
| rSP specific mAbs | End point values (ELISA) | Affinity (KD) | Surrogate Virus Neutralization Test (sVNT) (% of positive control) (1 mg/mL) | PRNT (1 mg/mL) |
|---|---|---|---|---|
| F459G1 | 19.5 ng/mL | 0.188 | 96.1% | PRNT50≥640; PRNT90 = 320 |
| F461G8 | 156 ng/mL | 8.06 | 96% | PRNT50 = 320; PRNT90 = 80 |
| F461G11 | 156 ng/mL | 9.66 | 96.2% | PRNT50≥640; PRNT90 = 320 |
| F461G14 | 4.9 ng/mL | 0.353 | 96% | PRNT50≥640; PRNT90 = 320 |
| F461G15 | 4.9 ng/mL | 0.212 | 96% | PRNT50≥640; PRNT90 = 320 |
| F461G16 | 3.1 ng/mL | 0.177 | 96.2% | PRNT50≥640; PRNT90 = 160 |
rSP: recombinant spike protein.